Rolando Brawer

Nov 04, 2016

Genomic Health has appointed Rolando Brawer as vice president of corporate development. He will be responsible for identifying growth opportunities to expand the company's Oncotype IG Genomic Intelligence Platform offerings. Prior to joining Genomic Health, Brawer held senior leadership positions in business development and licensing at Thermo Fisher Scientific and its subsidiary Life Technologies. 

More Like This

Aug 16, 2018

Jeffrey Henderson

Becton Dickinson has elected Jeffrey Henderson to its board of directors. Henderson is the non-executive chairman of the board of Qualcomm, serves on the boards of FibroGen and Halozyme Therapeutics, and is an advisory director to Berkshire Partners. He previously served as CFO of Cardinal Health for nearly 10 years and has also held positions at Eli Lilly and General Motors.

Aug 09, 2018

Albert Parker

OncoCyte has appointed Albert Parker as its chief operating officer. According to the company, Parker is an attorney and executive with more than 25 years of pharmaceutical, biotech, and healthcare experience. Prior to joining OncoCyte, Parker served as the managing shareholder of GC Legal Advisors, where he represented and advised public and privately held companies, primarily in the life sciences industry. Among other prior roles, Parker has also served as executive VP, general counsel, and corporate secretary at Sunovion Pharmaceuticals, senior VP and chief counsel for Wyeth Pharmaceuticals, and partner at Schnader Harrison Segal & Lewis.

Aug 09, 2018

Kathleen LaPorte

Precipio has appointed Kathleen LaPorte to its board as an independent member. She will replace Michael Allen Luther, who first served on the board of Transgenomic starting in 2014 and remained on it after that firm merged with Precipio.  

LaPorte was a general partner with Sprout Group from 1993 to 2004 and was a founder of New Leaf Venture Partners. She is also a cofounder of Health Tech Capital and was CEO of immuno-oncology diagnostic company Nodality. 

Aug 09, 2018

Hal Barron, Hans Bishop

Grail has appointed Hal Barron and Hans Bishop to its board. Barron is the CSO and president of R&D at GlaxoSmithKline. Prior to that, he served as president of R&D at Calico. He has also held management positions at Roche Pharmaceuticals and Genentech and is associate adjunct professor of epidemiology and biostatistics at the University of California, San Francisco. 

Bishop founded Juno Therapeutics in 2013 and was the firm's president and CEO until this past March when it was acquired by Celgene. He previously served as executive-in-residence at Warburg Pincus and is currently on the boards of Agilent Technologies and Celgene.

Aug 08, 2018

Mary Lake Polana

Chembio Diagnostics appointed Mary Lake Polana, a professor of clinical obstetrics, gynecology, and reproductive sciences at Yale University School of Medicine, to its board of directors. 

Polan focuses on reproductive health for women. She is a women's health researcher, and her work on ovarian function, reproductive endocrinology, and infertility has been published and cited throughout the scientific community. Polan has experience in leadership roles at several medical schools, and prior to Yale, she served as an adjunct professor in the obstetrics and gynecology department at Columbia University School of Medicine. Previously, Polan spent 15 years as the chair of the department of obstetrics and gynecology at Stanford University School of Medicine.

Aug 07, 2018

David Macdonald

First Light Biosciences has appointed David Macdonald its president, CEO, and board member. He was most recently CEO of Agendia, and before that was a division president, COO and vice president at Quest Diagnostics. 

Aug 06, 2018

Mitchell Nelles

CareDx Chief Operating Officer Mitchell Nelles told the company on July 31 that he intends to retire, effective Sept. 28, according to a document filed with the US Securities Exchange Commission. Nelles joined CareDx in 2007, when it was called XDx, as VP of R&D. Prior to that, Nelles served as VP of North American R&D at BioMérieux.

Aug 02, 2018

Eric Stawiski

Eric Stawiski has been appointed vice president of bioinformatics at MedGenome. He is tasked with scaling up the company's bioinformatics services and building new products and IP. He was previously at Genentech where he was a group leader for a team focused on analyzing RNA-seq, exome, and copy number data to identify potential driver genes and drug targets in cancers, as well as evaluating new sequencing technologies. 

Jul 31, 2018

Didier Hirsch, Robert McMahon, Karleen Oberton

Agilent Technologies said its senior VP and CFO Didier Hirsch will retire, effective Oct 31. The company has appointed Robert McMahon, currently CFO of Hologic, as his successor. McMahon will join Agilent on Aug. 3 as senior VP and will become CFO on Sept. 1 when Hirsch steps down from that post. Hirsch will continue as an active member of the executive staff until his retirement date at the end of the fiscal year and will work with McMahon to ensure a smooth transition.

Hirsch has served as Agilent's CFO since 2010. Before that, he had oversight of the corporate controllership and tax functions. He joined Agilent in 1999 as VP of treasury and investor relations. He also held various international finance positions at HP from 1989 until joining Agilent.
McMahon has served as Hologic's CFO since 2014. Prior to that, he spent 20 years with Johnson & Johnson, most recently as worldwide VP of finance and business development for Ortho Clinical Diagnostics. He also held a variety of financial leadership positions within Johnson & Johnson after joining the company in 1993.

Separately, Hologic said it would promote its current Chief Accounting Officer Karleen Oberton to replace McMahon as CFO. She joined Hologic in 2006 as corporate controller and was promoted to her current position in 2015. Prior to that, Oberton served as senior corporate controller for Immunogen, and as a senior audit manager for both Ernst Young and Arthur Andersen.

Jul 31, 2018

Rishi Kacker, Alexander Ford, Eric Evans, Lloyd Sanders

As part of Myriad Genetics' integration with recently acquired firm Counsyl, the company announced a number of personnel changes. Rishi Kacker, formerly Counsyl's senior VP of technology, will become Myriad's new chief technology officer. Alexander Ford, previously president of Myriad Genetic Laboratories, will be president of the company's women's health business unit, while Eric Evans, Counsyl's chief scientific officer, will now serve as the chief scientific officer of the women's health unit. Lastly, Lloyd Sanders, previously general manager of the oncology segment, will be president of Myriad's oncology business unit.

Jul 31, 2018

Mark McDonough

Mark McDonough has been named chief business officer at diagnostics and bioinformatics firm Phosphorus. McDonough was previously president and CEO of CombiMatrix, now part of Invitae. He also held senior executive positions at Pathwork Dx and Laboratory Corporation of America. Phosphorus offers genetics testing in fertility, cardiology, lipidology, and other indications. It also offers the Elements software platform for labs to deploy the company's genetic tests on-premise as a local solution.

Jul 31, 2018

Roy Baynes

Natera has appointed Roy Baynes to its board of directors. Baynes is chief medical officer at Merck and senior vice president and head of global clinical development at Merck Research Laboratories. He has also held several roles at Gilead Sciences and Amgen and is a member of the American Society of Hematology, American Society of Clinical Oncology, and American Association for Cancer Research. Prior to joining industry, Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute.

Jul 31, 2018

Mohsin Meghji

Mohsin Meghji has joined the board of Bioaffinity Technologies. Managing partner at merchant banking and advisory firm M-III Partners, Meghji replaces Barry Frankel. He founded M-III in late 2014. Prior to that, he was executive vice president and head of strategy at Springleaf Holdings and CEO of its captive insurance companies. Meghji is chairman of the board at Infrastructure & Energy Alternatives.

Jul 24, 2018

Ted Hull

Bako Diagnostics has appointed Ted Hull its CEO, effective Aug. 1. He succeeds Larry McCarthy who served as interim CEO and is Bako's chairman. Hull has more than 25 years of industry experience including 15 years at Genova Diagnostics where he was CFO then chairman and CEO. He was most recently managing partner of Ramble Ventures. 

Bako provides diagnostic and therapeutic services to the podiatric medical community with a focus on pathology for the lower extremity. Its testing menu includes epidermal nerve fiber density analysis, mass spectrometry for the identification of bacteria from culture specimens, and molecular genetics for detecting microorganisms and as a diagnostic aid in certain pathologic diagnoses.

Jul 24, 2018

George Church, David Walt, Kevin Chen

Molecular diagnostics firm NuProbe Global has formed a scientific advisory board and appointed a new member to its board of directors. The firm has named George Church and David Walt as members of the scientific board. Church and Walt are currently professors of genetics and pathology, respectively, at Harvard Medical School. The firm has also appointed Kevin Chen, founding partner at Biotrack Capital, as a member of the board of directors. Chen has previously led investment in healthcare companies including Beijing Genomics Institute (BGI), Betta Pharma, and Yuwell Medical.